Remember this has the best AI team and tech in the country at UNSW behind it whose sole purpose is to generate drug combinations for unmet clinical needs - so ho many more potential combinations are their for the taking. That's what I really like about this company as an opportunity, the amount of potential "shots on goal" seriously diversifies the risk profile and offers great leverage at this market cap.
